Fecal microbiota transplantation for irritable bowel syndrome: Current evidence and perspectives

doi:10.3748/wjg.v30.i16.2179

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 16

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2155)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

1853

Sum=1905

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

106

Sum=151

Apr 28, 2024 (publication date) through Nov 20, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Apr 28, 2024; 30(16): 2179-2183
Published online Apr 28, 2024. doi: 10.3748/wjg.v30.i16.2179

Fecal microbiota transplantation for irritable bowel syndrome: Current evidence and perspectives

Cong Dai, Yu-Hong Huang, Min Jiang

Cong Dai, Yu-Hong Huang, Min Jiang, Department of Gastroenterology, First Hospital of China Medical University, Shenyang 110001, Liaoning Province, China

Author contributions: Jiang M had the original idea for the paper, formulated the protocol and contributed to data abstraction and analysis; Dai C and Jiang M wrote the paper and incorporated the comments from other authors and peer reviewers. All authors reviewed and approved the final draft of the paper.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Min Jiang, Doctor, PhD, Professor, Department of Gastroenterology, First Hospital of China Medical University, No. 92 of Beier Road, Heping District, Shenyang 110001, Liaoning Province, China. congdai2006@126.com

Received: November 25, 2023
Peer-review started: November 25, 2023
First decision: February 8, 2024
Revised: February 14, 2024
Accepted: April 1, 2024
Article in press: April 1, 2024
Published online: April 28, 2024
Processing time: 153 Days and 3.5 Hours

Core Tip

Core Tip: Fecal microbiota transplantation (FMT) has emerged as a efficacious intervention for Clostridium difficile infection and holds promise as a therapeutic modality for irritable bowel syndrome (IBS). The utilization of FMT in the treatment of IBS has undergone scrutiny in numerous randomized controlled trials, yielding divergent outcomes. The current frontier in this field seeks to elucidate these variations, underscore the existing knowledge gaps that necessitate exploration, and provide a guideline for successful FMT implementation in IBS patients. At the same time, the application of FMT as a treatment for IBS confronts several challenges.